PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 9974100-2 1999 In this model, co-treatment with ibotenate and a vasoactive intestinal peptide antagonist (VA) aggravates the excitotoxic lesions, suggesting a protective role of endogenous VIP. Ibotenic Acid 33-42 vasoactive intestinal polypeptide Mus musculus 174-177 10027860-5 1999 The goal of the present study was to assess the protective properties of systemically injected VIP analogs against ibotenate-induced excitotoxic white matter lesions in newborn mice. Ibotenic Acid 115-124 vasoactive intestinal polypeptide Mus musculus 95-98 10027860-7 1999 RO-25-1553, a long-lasting cyclic VIP analog, and stearyl-norleucine-VIP, a fatty derivative of VIP, reduced ibotenate-induced white matter cysts by up to 87% and 84%, respectively, when injected i.p. Ibotenic Acid 109-118 vasoactive intestinal polypeptide Mus musculus 69-72 10027860-7 1999 RO-25-1553, a long-lasting cyclic VIP analog, and stearyl-norleucine-VIP, a fatty derivative of VIP, reduced ibotenate-induced white matter cysts by up to 87% and 84%, respectively, when injected i.p. Ibotenic Acid 109-118 vasoactive intestinal polypeptide Mus musculus 69-72 10027860-11 1999 Furthermore, RO-25-1553 and stearyl-norleucine-VIP still induced significant neuroprotection of the developing white matter when injected systemically 8 and 12 h, respectively, after ibotenate, establishing these peptides as therapeutic agents in this murine model. Ibotenic Acid 183-192 vasoactive intestinal polypeptide Mus musculus 47-50 10676440-6 1999 Previous studies had shown that VIP-treated cultured astrocytes release growth factors including activity-dependent neurotrophic factor (ADNF) and that a 14-amino-acid peptide derived from ADNF protected the developing white matter against ibotenate. Ibotenic Acid 240-249 vasoactive intestinal polypeptide Mus musculus 32-35 9218516-5 1997 The goal of this study was to assess the protective role of VIP against excitotoxic lesions induced by ibotenate in developing mouse brain. Ibotenic Acid 103-112 vasoactive intestinal polypeptide Mus musculus 60-63 9218516-6 1997 VIP cotreatment reduced ibotenate-induced microgyric-like cortical lesions and white matter cysts by up to 77 and 85%, respectively. Ibotenic Acid 24-33 vasoactive intestinal polypeptide Mus musculus 0-3 12106022-8 1990 Thus, based on this metabotropic action, EAA can be categorized into the following classes: (i) those that potentiate the effect of VIP, such as glutamate, aspartate, kainate and ibotenate; (ii) those that inhibit the effect of VIP, such as l-homocysteate and quisqualate; and (iii) those that are ineffective, such as NMDA and d-homocysteate. Ibotenic Acid 179-188 vasoactive intestinal polypeptide Mus musculus 132-135 12106022-5 1990 Furthermore, ibotenate also potentiated the effect of VIP on cAMP formation, while l-homocysteate exhibited an inhibitory action. Ibotenic Acid 13-22 vasoactive intestinal polypeptide Mus musculus 54-57 12106022-9 1990 The effects of glutamate or ibotenate on VIP-stimulated cAMP formation were completely inhibited by l-phosphoserine and only partially by kynurenate. Ibotenic Acid 28-37 vasoactive intestinal polypeptide Mus musculus 41-44